June 27, 2013

PRESS RELEASE

Mitsubishi Tanabe Pharma Corporation

VIVUS gains MAA approval for TA-1790 in the EU

VIVUS (head office: Mountain View, California, U.S.) announced on June 26, 2013, that the company obtained marketing authorization from the European Commission for TA-1790 (generic name: avanafil), a phosphodiesterase type5 (PDE5) inhibitor, which the company has developed as a treatment of erectile dysfunction (ED). The marketing authorization follows a positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) in April, 2013.

TA-1790 was discovered for the treatment of ED by Mitsubishi Tanabe Pharma Corporation, (Head office: Osaka, Japan) which is expected to have a rapid onset and fewer side effects. In February 2001, Mitsubishi Tanabe Pharma Corporation licensed the development and commercial rights of the compound to VIVUS for the entire world excluding Japan and a certain part of Asia. VIVUS will commercialize it under the brand name SPEDRA™ in the EU.

In the US, VIVUS obtained NDA approval for TA-1790, STENDRA™ from FDA as a treatment of ED in April 2012, and in South Korea, it is approved, and has been marketed by JW Pharmaceutical (Head office: Seoul, Korea) under the brand name Zepeed® from October, 2011.

<Media enquiry>
Corporate Communications Department
Phone: +81 6-6205-5211